NEW YORK – In 2023, GenomeWeb readers couldn't get enough news about Illumina as the company continued to push ahead with the integration of liquid biopsy company Grail, which it acquired in August 2021, despite sustained opposition from several fronts including regulators and shareholders. Illumina finished 2023 by announcing its intention to unwind the deal.
Against this backdrop, in June Illumina also announced multiple rounds of layoffs — as did many companies in the omics research tools and molecular diagnostics industries, with similar cutbacks at Thermo Fisher Scientific, Natera, Guardant Health, and Twist Bioscience attracting readers' attention.
Meanwhile, January's JP Morgan Healthcare Conference once again proved to be a premier newsmaking event as large numbers of GenomeWeb readers clicked through to read dispatches on executive presentations from multiple companies of interest. Readers can expect similar reports from the 2024 edition of the JPM Healthcare meeting starting next week.
Finally, one major acquisition particularly piqued readers' interest in 2024: Thermo Fisher's $3.1 billion October purchase of Swedish proteomics firm Olink.
Here are the 10 most-read stories on GenomeWeb from 2023: